New presurgery treatment combination more effective for women with triple-negative breast cancer

(American Association for Cancer Research) Adding the chemotherapy drug carboplatin and/or the antibody therapy bevacizumab to standard presurgery chemotherapy increased the number of women with triple-negative breast cancer who had no residual cancer detected at surgery, according to results of a randomized, phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news